CEREBRAL GLUCOSE METABOLIC PET STUDY

DATE: 1/12/2006

PROCEDURE:  The patient was given an IV injection of 18-fluoro-2-deoxyglucose (FDG).  After a standard uptake period, the patient was imaged on a Siemens/CTI PET scanner with multiple five-minute images.  After removing static image frames containing patient motion, the remaining images were summed, reconstructed and resliced into transaxial and coronal images.

FDG DOSE: [10]  mCi

SESSION NUMBER: p00000

CORRELATIVE STUDIES: None

COMPARISON: None

CLINICAL HISTORY: The patient is a [...]-year-old [fe]male with past medical history significant for [...], who is referred for evaluation of [...].

FINDINGS: 

Normal metabolic activity is seen throughout the cortical structures, bilateral basal ganglia, thalami and the cerebellum. 

No areas of abnormal tracer uptake are identified.

The interhemispheric, interthalamic, intercaudate and intersulcal distances are within normal limits.

CONCLUSIONS:

There is no localizing evidence of an epileptogenic focus by FDG PET criteria.

Mild relative hypometabolism of the [...]. In the appropriate clinical setting, this may represent a zone of epileptogenesis.

There is no evidence of a progressive neurodegenerative process by FDG PET criteria.

Thank you for referring this patient to the UCLA Nuclear Medicine Clinic.

I, [...], M.D., Ph.D., have reviewed this Nuclear Medicine study personally, and am in full agreement with the findings of the report presented here.